2-(3-Methyl-2,6-dioxo-1,2,3,6-tetrahydro-7h-purin-7-yl)acetic acid, 97%, 100mg

Ethyl 2,4-dioxohexanoate, 95.0%, 5g

E-Plan phase EPLPHi 10x/0.25 infinity corrected IOS objective. Working distance 5.95 mm

2-METHYL-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENOL, 95.0%, 100mg

6-Methyl-2-aminobenzoxazol, 95.0%, 10g

3-Chloro-2-fluorobenzamide, 97%, 10g

Benzo[b]naphtho[1,2-d]thiophene, 97.0%, 5g

tert-Butyl 4-formyl-5-methoxy-7-methyl-1H-indole-1-carboxylate, 97.0%, 250mg

tert-Butyl 4-(2-aminopyridin-4-yl)piperazine-1-carboxylate, 95.0%, 10g

5-(4-(((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)methyl)-3,5-dimethoxyphenoxy)pentanoic acid, 97%, 1g

3-Bromo-4-nitro-1H-pyrazole, 95.0%, 1g

1-[3-(Trifluoromethyl)phenyl]ethylamine, 95.0%, 25g

1-(3,3-Diphenyl-N-methylpropylamino)-2-methyl-2-propanol, 95.0%, 25g